Key clinical point: For patients with early triple-negative breast cancer, adding capecitabine to standard adjuvant chemotherapy may extend disease-free survival.
Major finding: The 5-year disease-free survival was 86.26% in the capecitabine group, compared with 80.23% in the control group (P = .038).
Study details: An open-label, phase 3 trial involving 585 patients with triple-negative breast cancer.
Disclosures: The investigators reported no disclosures.
Li J et al. SABCS 2019, Abstract GS1-08.